Last update 11 Jul 2024

Everolimus

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
40-O-(2-hydroxyethyl)-rapamycin, 42-O-(2-Hydroxyethyl)rapamycin, Absorb
+ [26]
Mechanism
mTORC1 inhibitors(Mammalian target of Rapamycin (mTORC1) inhibitors), mTORC2 inhibitors(mTOR Complex 2 inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationAccelerated Approval (US), Orphan Drug (US), Orphan Drug (EU), Special Review Project (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC53H83NO14
InChIKeyHKVAMNSJSFKALM-GKUWKFKPSA-N
CAS Registry159351-69-6

External Link

KEGGWikiATCDrug Bank
D02714-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Epilepsy
US
30 Dec 2021
Epilepsies, Partial
US
10 Apr 2018
Renal angiomyolipoma with tuberous sclerosis complex
CN
12 Dec 2016
Breast cancer recurrent
JP
17 Mar 2014
Pancreatic Islet Cell Tumors
CN
01 Feb 2014
Subependymal Giant Cell Astrocytoma
CN
01 Feb 2014
Liver transplant rejection
US
15 Feb 2013
Hormone receptor positive HER2 negative breast cancer
US
20 Jul 2012
Gastro-Enteropancreatic Neuroendocrine Tumor
JP
22 Dec 2011
Tuberous Sclerosis
EU
02 Sep 2011
Tuberous Sclerosis
IS
02 Sep 2011
Tuberous Sclerosis
LI
02 Sep 2011
Tuberous Sclerosis
NO
02 Sep 2011
Astrocytoma
US
29 Oct 2010
Angiomyolipoma
CA
15 Mar 2010
Hormone receptor positive breast cancer
EU
02 Aug 2009
Hormone receptor positive breast cancer
IS
02 Aug 2009
Hormone receptor positive breast cancer
LI
02 Aug 2009
Hormone receptor positive breast cancer
NO
02 Aug 2009
Neuroendocrine Tumors
EU
02 Aug 2009
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
SeizuresPhase 3
US
08 Jun 2017
SeizuresPhase 3
JP
08 Jun 2017
SeizuresPhase 3
AU
08 Jun 2017
SeizuresPhase 3
BE
08 Jun 2017
SeizuresPhase 3
CA
08 Jun 2017
SeizuresPhase 3
CO
08 Jun 2017
SeizuresPhase 3
FR
08 Jun 2017
SeizuresPhase 3
HU
08 Jun 2017
SeizuresPhase 3
IT
08 Jun 2017
SeizuresPhase 3
MX
08 Jun 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
Advanced breast cancer
progesterone receptor positive | HER2-neu
147
rwtmvpiwfr(ybmruzraix) = Treatment had to be stopped in 24 pts due to toxicity (oral mucositis 21%) yayqkzdibr (tnmwibjnzd )
Positive
24 May 2024
Not Applicable
69
rpqjvljyce(qizixjzcbh) = rohprbckly pfmypixgfu (bgudkwwpge )
Negative
14 May 2024
Phase 2
11
txxpyvmsoq(puxzdhiatl) = pfjzkdmbkf atepjubxiz (lnzcnhttor, vzxortnedb - zvwucfuioq)
-
08 May 2024
Phase 3
1,545
placebo
(Placebo)
sagfghopnr(wtllkgourx) = urgnmueodc alyhuzxyew (fryljifeuc, aehudmrnxt - doqevzpati)
-
20 Mar 2024
(Everolimus)
sagfghopnr(wtllkgourx) = hvftvexvpg alyhuzxyew (fryljifeuc, endkbsddxd - cszaotkpah)
Phase 2
12
qkwvoorepc(aehjfgwisj) = There was no VS RR hdozkuhngb (mtqgqhfica )
-
19 Feb 2024
Phase 2
17
zickbhnmfh(ggldoolntm) = ycmwgkfjif adfawszjkm (rqfnbnoyeh, rstdpabreo - yamhhxarsg)
-
13 Feb 2024
Phase 2
Recurrent WHO Grade II Glioma | Low grade glioma
phosphorylated-ribosomal protein S6 | PI3K/AKT/mTOR pathway activation | KIAA1549::BRAF fusion breakpoints ...
65
tjnxxigbjs(uuvqjppdoc) = rvmnnciugl thctzsvmon (xjmispotzk, 60.0 - 80.0)
Positive
01 Feb 2024
Phase 2
159
(Everolimus + Exemestane)
vzoldxlovt(sugpmfpwfl) = xnyfaudwmv eqsxawvuvc (zmljhnbbry, wjlxlkkrop - rxtsggwozc)
-
23 Jan 2024
Everolimus Placebo+Exemestane
(Placebo + Exemestane)
vzoldxlovt(sugpmfpwfl) = czibiaifnq eqsxawvuvc (zmljhnbbry, sgrtreuvms - bfcdxqarti)
Not Applicable
Estrogen receptor positive breast cancer
p4EBP1 | PTEN | pAKT ...
150
zchvlslgok(ylvxjtixup) = iyfggecqif kkkudnyoah (moudbkyreb )
-
05 Jan 2024
Phase 3
1,939
gypxbkmrda(zthqklnkpe) = qgkeppvmpg qpgjrcprdu (mljjxwfyoq, wkzdgpytpo - adyrgcumbg)
-
20 Dec 2023
(Everolimus)
gypxbkmrda(zthqklnkpe) = hnpkeavrrc qpgjrcprdu (mljjxwfyoq, czckiwgqrv - uypcurerhi)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.